Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 19Withdrawn 2Unknown 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Fluconazole × Clear all
NCT03036046 2018-02-15

SAFEGUARDFP

F2G Biotech GmbH

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02532192 2016-01-06

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡